Literature DB >> 21605716

Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT.

Masako Ito1, Toshitaka Nakamura, Masao Fukunaga, Masataka Shiraki, Toshio Matsumoto.   

Abstract

The effects of an active vitamin D analog, eldecalcitol (ELD), on bone mineral density (BMD), bone geometry, and biomechanical properties of the proximal femur were investigated by using clinical CT. The subjects--a subgroup of a recent randomized, double-blind study comparing anti-fracture efficacy of ELD with alfacalcidol (ALF) - constituted 193 ambulatory patients with osteoporosis (189 postmenopausal women and 4 men aged 52-85 years, average ± SD: 70.9 ± 6.92 years) enrolled at 11 institutions. Multidetector-row CT data was acquired at baseline and at completion of 144 weeks' treatment. Cross-sectional densitometric and geometric parameters of the femoral neck were derived from three-dimensional CT data. Biomechanical properties including cross-sectional moment of inertia (CSMI), section modulus (SM) and buckling ratio (BR) of the femoral neck, and CSMI of the femoral shaft were also calculated. We found that, (1) with respect to the femoral neck cross-sectional parameters (total bone), in the ALF group, volumetric BMD (vBMD) decreased but bone mass was maintained and cross-sectional area (CSA) increased. In contrast, ELD maintained vBMD with a significant increase in bone mass and a trend toward increased CSA. (2) With respect to the femoral neck cross-sectional parameters (cortex), cortical thickness decreased in the ALF group, but was maintained in the ELD group. In the ALF group, vBMD and bone mass increased, and CSA was maintained. In the ELD group, vBMD, CSA, and bone mass increased. (3) With respect to the biomechanical properties of the femoral neck, ELD improved CSMI and SM to a greater extent than did ALF. BR increased in both the ALF and ELD groups. (4) With respect to the femoral shaft parameters, overall the results of bone geometry and CSMI of the femoral shaft were very consistent with the results for the femoral neck; however, cortical vBMD of the femoral shaft decreased significantly in both the ELD and ALF groups. In conclusion, our longitudinal analysis of hip geometry by clinical CT revealed the unexpected potential of ELD to increase cortical CSA, vBMD, and bone mass, and to maintain cortical thickness, probably through the more potent effect of ELD in mitigating endocortical bone resorption than ALF. By improving the biomechanical properties of the proximal femur, ELD may have the potential to reduce the risk of hip fractures.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21605716     DOI: 10.1016/j.bone.2011.05.002

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  18 in total

1.  Can PET-CT imaging and radiokinetic analyses provide useful clinical information on atypical femoral shaft fracture in osteoporotic patients?

Authors:  C Haile Chesnut; Charles H Chesnut
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

2.  Effects of eldecalcitol on bone and skeletal muscles in glucocorticoid-treated rats.

Authors:  Hayato Kinoshita; Naohisa Miyakoshi; Yuji Kasukawa; Sadaoki Sakai; Ayako Shiraishi; Toyohito Segawa; Kentaro Ohuchi; Masashi Fujii; Chie Sato; Yoichi Shimada
Journal:  J Bone Miner Metab       Date:  2015-05-06       Impact factor: 2.626

3.  Spotlight on eldecalcitol in osteoporosis.

Authors:  Mark Sanford; Paul L McCormack
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

Review 4.  Eldecalcitol: a review of its use in the treatment of osteoporosis.

Authors:  Mark Sanford; Paul L McCormack
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

5.  Eldecalcitol improves muscle strength and dynamic balance in postmenopausal women with osteoporosis: an open-label randomized controlled study.

Authors:  Kimio Saito; Naohisa Miyakoshi; Toshiki Matsunaga; Michio Hongo; Yuji Kasukawa; Yoichi Shimada
Journal:  J Bone Miner Metab       Date:  2015-07-25       Impact factor: 2.626

Review 6.  Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol.

Authors:  Toshio Matsumoto; Toshiyuki Takano; Hitoshi Saito; Fumiaki Takahashi
Journal:  Bonekey Rep       Date:  2014-03-05

Review 7.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

8.  Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D.

Authors:  Junichi Kikuta; Shunsuke Kawamura; Fumie Okiji; Mai Shirazaki; Sadaoki Sakai; Hitoshi Saito; Masaru Ishii
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

9.  Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis.

Authors:  Hiroshi Hagino; Toshiyuki Takano; Masao Fukunaga; Masataka Shiraki; Toshitaka Nakamura; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2012-11-06       Impact factor: 2.626

10.  Comparative effect of eldecalcitol and alfacalcidol on bone microstructure: A preliminary report of secondary analysis of a prospective trial.

Authors:  Xiaolin Ni; Juan Feng; Yan Jiang; Li Zhang; Wei Yu; Ou Wang; Mei Li; Xiaoping Xing; Toshio Matsumoto; Weibo Xia
Journal:  Osteoporos Sarcopenia       Date:  2021-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.